drugset / Trial / NCT07051486
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.
Timeline
- Start
- 2025-10-11
- Primary completion
- 2026-02
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |
Indications
No indication recorded.